Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

Santhera facing long delay for muscular dystrophy drug in US

Santhera facing long delay for muscular dystrophy drug in US In recent months the FDA has rejected BioMarin's exon-skipping therapy Kyndrisa (drisapersen) - which has now been abandoned after also being turned down by the EMA - as well as PTC

BioMarin gives up on muscular dystrophy drug

BioMarin gives up on muscular dystrophy drug Makes ‘difficult but necessary’ decision to abandon exon-skipping therapy Kyndrisa. BioMarin has said it will stop development of its Duchenne muscular dystrophy (DMD) drug Kyndrisa after another regulatory knockback. ... The announcement marks the

Sanofi takeover bid rebuffed by Medivation

Sanofi takeover bid rebuffed by Medivation Meanwhile, Medivation has a well-regarded cancer pipeline headed by PARP inhibitor talazoparib (MDV3800) - licensed from BioMarin - in phase III trials for the treatment of patients with breast cancer whose BRCA

FDA rejects PTC's application for muscular dystrophy drug

FDA rejects PTC's application for muscular dystrophy drug Translarna is intended to treat DMD caused by nonsense mutations in the dystrophin gene and works via a slightly different mechanism to other DMD therapies coming through the pipeline, including

Deal Watch October 2015

Deal Watch October 2015 This month's deal between Merck Serono (Merck KGaA) and BioMarin is a good example of this approach. ... Acquisition - company. 580. Merck Serono/ BioMarin. Kuvan and pegvaliase (Kuvan marketed; pegvaliase p3).

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...

Infographics